Transcriptomics

Dataset Information

0

Gene expression profilings for prostate cancer cells after inhibition of PARP1 or PARP2 using pharmaceutical or siRNA-based approaches


ABSTRACT: Androgen receptor (AR) signaling is a key driver of prostate cancer (PCa) growth and progression. Understanding the factors influencing AR-mediated transcription provides new opportunities for therapeutic intervention. We have previously discovered that a genetic variant in one of the DNA repair genes, PARP2, is associated with aggressive PCa. Here, we show that a high expression level of PARP2 in PCa tumors is associated with high Gleason scores and biochemical recurrence using The Cancer Genome Atlas (TCGA) dataset. Functional studies reveal that PARP2 enhances AR-mediated gene expression through interacting with the pioneer factor FOXA1 and facilitating AR recruitment to the enhancer regions genome-wide in PCa cells. Selective targeting of PARP2, but not PARP1, by genetic or pharmacological means blocks interaction between PARP2 and FOXA1, which in turn attenuates AR-mediated transcription and inhibits AR-positive PCa growth. SIGNIFICANCE: Current anti-androgens act through blocking ligand binding or inhibiting androgen synthesis. Selective targeting of PARP2 may provide a novel therapeutic approach for AR inhibition by disruption of FOXA1 function, which may be beneficial to patients, irrespective of their DNA repair defect status and, more importantly, when direct AR-targeted therapies fail.

ORGANISM(S): Homo sapiens

PROVIDER: GSE114273 | GEO | 2019/06/24

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2019-06-24 | GSE114274 | GEO
2023-10-11 | GSE225196 | GEO
2023-07-19 | GSE225205 | GEO
2013-02-15 | GSE44319 | GEO
2017-10-27 | PXD008056 | Pride
2013-03-16 | E-GEOD-45201 | biostudies-arrayexpress
2014-03-20 | E-GEOD-52627 | biostudies-arrayexpress
2014-12-12 | E-GEOD-52201 | biostudies-arrayexpress
2021-03-01 | PXD011974 | Pride
2013-03-16 | GSE45202 | GEO